Developer · ENP · Australia

Entropy Neurodynamics Limited

Clinical-stage biotechnology company based in Melbourne, Australia (ASX: ENP), formerly Tryptamine Therapeutics Limited (ASX: TYP); the name and ASX code changed in November 2025 after approval at the 2025 AGM. It develops precision-controlled psychedelic therapies built on TRP-8803, an intravenously infused psilocin formulation given with psychotherapy, and uses TRP-8802 (oral synthetic psilocybin) as a pathfinder in binge eating disorder, irritable bowel syndrome and fibromyalgia. Its Canadian subsidiary Tryp Therapeutics Inc. sponsored the first TRP-8803 healthy-volunteer study.

1compound
1program
1indication
Phase 1lead asset

Phase distribution

  • Phase 11

Modality

  • Psychedelic 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Aug 4, 2026PartnershipHREC approval and new Swinburne research agreement for 72-patient, eight-indication TRP-8803 basket studyHuman Research Ethics Committee approval secured for a Phase 1b/2a open-label basket study of TRP-8803 in 72 participants across nine cohorts of eight: anorexia nervosa, body dysmorphic disorder, OCD, generalised anxiety disorder, PTSD, treatment-resistant depression (two cohorts, on and off antidepressants), fibromyalgia and irritable bowel syndrome. Each participant gets two doses about two weeks apart with psychotherapy; the primary endpoint is safety. A new Clinical Trial Research Agreement was signed with Swinburne. CTN acknowledgement and site governance approvals were still outstanding.TRP-8803 (IV-infused psilocin)source ↗
  • Aug 2026PartnershipPre-Clinical Trial Agreement with UCSF for a proposed US Phase 2 of TRP-8803 vs escitalopram in MDDEntropy signed a pre-Clinical Trial Agreement with the University of California, San Francisco to develop a proposed US Phase 2 trial comparing TRP-8803 with escitalopram in up to 80 young adults with major depressive disorder, led by Professor Robin Carhart-Harris. Entropy would sponsor the FDA IND. The trial is targeted to start in H1 CY2027, subject to regulatory clearance.TRP-8803 (IV-infused psilocin)source ↗
  • Q3 2026PartnershipGMP manufacturing agreement with BioCina for TRP-8803Development and Manufacturing Services Agreement with BioCina, an Australian CDMO, for analytical verification, engineering batches and GMP manufacture of placebo and active TRP-8803 drug product, intended to support international Phase 2/3 development. Entropy keeps full ownership of the TRP-8803 IP.TRP-8803 (IV-infused psilocin)source ↗
  • Nov 2025Corporate rebrand / name changeTryptamine Therapeutics renamed Entropy Neurodynamics; ASX code TYP becomes ENPShareholders approved the change of name from Tryptamine Therapeutics Limited to Entropy Neurodynamics Limited at the 2025 Annual General Meeting; the change took effect in November 2025, with the ASX code changing from TYP to ENP.TRP-8803 (IV-infused psilocin)source ↗
  • Apr 10, 2025PartnershipSwinburne University signs clinical trial research agreement with Tryptamine Therapeutics for IV psilocin in BEDSwinburne University of Technology signed a clinical trial research agreement with Tryptamine Therapeutics to run what it called the world's first trial of intravenously administered psilocin (TRP-8803) in binge eating disorder. The research lead is Professor Susan Rossell.TRP-8803 (IV-infused psilocin)source ↗

Catalysts · 1 upcoming · 2 reported

Recently reported

  • 2026-09-15met

    TRP-8803 (IV-infused psilocin)forBinge eating disorderInterim analysis

    Cohort 1 12-week durability: all six patients kept a clinically meaningful improvement; 3/6 had no binge-eating episodes across the 84-day follow-up; weekly binge episodes 73% below baseline; anxiety -50%, depression -42%, quality of life +61%.

    source ↗

  • 2026-07-07met

    TRP-8803 (IV-infused psilocin)forBinge eating disorderTopline data

    Cohort 1 topline (n=6, 140-minute regimen): 100% clinically meaningful improvement (>=30% from baseline), 50% (3/6) complete remission (zero binge episodes in the 4 weeks after treatment), 74% reduction in weekly binge-eating episodes, GAD-7 -58%, PHQ-9 -57%.

    source ↗

Recent activity

  • Sep 15, 2026ReadoutTRP-8803 (IV-infused psilocin)·Binge eating disordermetCohort 1 12-week durability: all six patients kept a clinically meaningful improvement; 3/6 had no binge-eating episodes across the 84-day follow-up; weekly binge episodes 73% below baseline; anxiety -50%, depression -42%, quality of life +61%.source ↗
  • Jul 7, 2026ReadoutTRP-8803 (IV-infused psilocin)·Binge eating disordermetCohort 1 topline (n=6, 140-minute regimen): 100% clinically meaningful improvement (>=30% from baseline), 50% (3/6) complete remission (zero binge episodes in the 4 weeks after treatment), 74% reduction in weekly binge-eating episodes, GAD-7 -58%, PHQ-9 -57%.source ↗
  • Oct 14, 2025Phase changeTRP-8803 (IV-infused psilocin)·Binge eating disorderPhase 1First patient enrolled at Swinburne University and a 4-week baseline assessment begun. The trial will recruit 12 BED patients in two cohorts, each given two TRP-8803 doses 14 days apart with supportive therapy.source ↗
  • Apr 17, 2025Phase changeTRP-8803 (IV-infused psilocin)·Binge eating disorderPhase 1BED-IV study registered on ANZCTR (ACTRN12625000330448), sponsor Tryptamine Therapeutics: 'A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803)... Among Adult Patients with Binge Eating Disorder', target 12 participants, anticipated first enrolment 2025-09-01.source ↗

Competitive landscape

Other companies developing against Entropy Neurodynamics Limited's targets or indications.